Therefore, further secondary outcomes will explore behavioral indicators (postoperative cognitive decline or POCD and delirium) and biological markers (interleukin-6 [IL6], C-reactive protein [CRP], neutrophil gelatinase–associated lipocalin [NGAL], and translocator protein [TPSO]) with established neuroinflammatory underpinnings [16-20] to see whether the primary pain outcome has a statistical relationship to these neuroinflammatory-related metrics. The gene discussed is IL6; the disease is Mental deterioration.